IL-22 may serve as a biomarker of response to TNFi and IL-17i in PsA

Key clinical point: Interleukin-22 (IL-22) can be used as a biomarker to predict response to tumor necrosis factor inhibitors (TNFi) and IL-17 inhibitors (IL-17i) in patients with psoriatic arthritis (PsA).

Major finding: After 1 year of IL-17i therapy, a higher proportion of patients with low vs high IL-22 levels achieved Disease Activity in PsA (DAPSA) remission (90% vs 15.3%, P = .0006) and Minimal Disease Activity (MDA; 100% vs 46.1%, P = .0075), with the rate of achieving DAPSA remission and MDA at 1 year significantly higher in patients with high IL-22 levels who received TNFi vs IL-17-i and in patients with low IL-22 levels who received IL-17i vs TNFi.

Study details: Findings are from a retrospective study including 47 patients with PsA who were treated with TNFi or IL-17i for ≥1 year.

,

Disclosures: This study was partly supported by Research on Rare and Interactable Diseases and Research Grant-In-Aid for Scientific Research by the Ministry of Health, Labour, and Welfare of Japan; and other sources. Y Tanaka and S Nakayamada declared receiving consulting fees, speaking fees, honoraria, and research grants from several sources.

Source: Miyagawa I et al. Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study. Arthritis Res Ther. 2022;24:86 (Apr 15). Doi: 10.1186/s13075-022-02771-4